Monitor for any subsequent Form 4 filings that may indicate insider buying or selling by the new CFO, which could signal conviction in the company's outlook.
SNDX drugs
SNDX drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 13 $9.45entry
- T+1 · 19h ago −3.39%α −1.47% · $9.13
- T+5 · in 3d Pending
- T+20 · in 27d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Aaron Ondrey filed a Form 3 initial statement of beneficial ownership after becoming Chief Financial Officer of Syndax Pharmaceuticals. The filing reports no securities owned and is a routine compliance document with no trading or financial impact.
Key Facts
- Aaron Ondrey appointed Chief Financial Officer of Syndax Pharmaceuticals Inc.
- Form 3 filed on 2026-11-12, reporting period 2026-11-09.
- No securities ownership reported in the filing.
Financial Impact
No financial impact; routine insider appointment filing.
Risk Factors
- No material risks identified from this filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 3 Filing (Primary) | 0001193125-26-458245 |
| Document: 0001193125-26-458245-index.html | 0001193125-26-458245 |
| Document: 0001193125-26-458245.txt | 0001193125-26-458245 |
Track record
16 reports on SNDX
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 12, 20264d ago 3 Neutral 1/10 Viewing Entry $9.45 Now $9.13 −3.39% settles Feb 11
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $9.49 Now $9.13 −3.79% settles Feb 8
- Nov 9, 20267d ago Press Release Neutral 2/10 Entry $9.49 Now $9.13 −3.79% settles Feb 8
- Nov 2, 202614d ago 8-K Neutral 5/10 No price data
- Nov 2, 202614d ago Press Release Neutral 2/10 No price data
- Nov 2, 202614d ago Press Release Neutral 5/10 Entry $14.29 Now $9.13 −36.11% settles Feb 1
- Oct 29, 202618d ago 144 Neutral 2/10 Entry $13.65 Now $9.13 −33.11% settles Jan 28
- Jul 14, 202617w ago 8-K Bullish 7/10 Entry $24.13 to $17.03 Now $9.13 −62.16% ▼ −29.42% −32.80% vs SPY
- Jul 1, 202619w ago Press Release Neutral 2/10 Entry $21.82 to $18.20 Now $9.13 −58.16% ▼ −16.59% −20.16% vs SPY
- Jun 11, 202622w ago Press Release Bullish 7/10 Entry $17.91 to $20.56 Now $9.13 −49.02% ▲ +14.80% +10.40% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers